• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic
liver disease globally and is currently estimated to affect up to 38% of the global adult …

QRISK algorithms use data from millions of people to help clinicians identify individuals at
high risk of cardiovascular disease (CVD). Here, we derive and externally validate a new …

Obesity and cardiometabolic disease often, but not always, coincide. Distinguishing
subpopulations within which cardiometabolic risk diverges from the risk expected for a given …

In high-income countries, rates of atherosclerotic complications in type 2 diabetes have
declined markedly over time due to better management of traditional risk factors including …

Metabolic comorbidities are common in patients with cardiorenal disease; they can cause
atherosclerotic cardiovascular disease (ASCVD), speed progression, and adversely affect …

Fatty liver plays a pivotal role in the pathogenesis of the metabolic syndrome and type 2
diabetes. According to an updated classification, any individual with liver steatosis and one …

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality and
morbidity worldwide. Low-density lipoprotein cholesterol (LDL-C) is one of the most …

Aim To investigate the real‐world utilization and comparative clinical outcomes of injectable
and oral semaglutide in individuals with type 2 diabetes (T2D) with the aim of enhancing …